ClinicalTrials.gg
CompletedNCT03959488Updated Sep 21, 2023Results posted

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

A Phase 2/3 interventional study of MEDI8897 and Palivizumab in Respiratory Syncytial Virus Infections, sponsored by AstraZeneca. Completed at 128 sites in 26 countries. Open to participants aged 0 Years to 1 Year. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by AstraZeneca · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
925
Allocation
Randomized
Ages
0 Years to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.

Enrollment
4th of 12
925 · median 239
Started
2019
with 1 other
Phase 2/3
Only one
of the 14
Registered
11th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 2/3, and was the 11th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 0 Years to 1 Year · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.

Read the detailed description

This study is a pivotal Phase 2/3 randomized, double-blind, palivizumab-controlled study to evaluate the safety, pharmacokinetics (PK), anti-drug antibody (ADA) response, and descriptive efficacy for MEDI8897 in high-risk infants eligible to receive palivizumab when entering their first or second RSV season (Season 1 or Season 2, respectively). Approximately 900 palivizumab-eligible infants entering their first RSV season will be enrolled into one of 2 cohorts: (1) preterm cohort, including approximately 600 preterm infants (≤ 35 weeks gestational age [GA]) without CLD/CHD, or (2) CLD/CHD cohort, including approximately 300 infants with CLD of prematurity or hemodynamically significant CHD. A minimum of 100 infants with hemodynamically significant CHD will be enrolled. Within each cohort, randomization will be stratified by hemisphere (northern, southern) and subject age at the time of Season 1 randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months).

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory Syncytial Virus Infections
  • Preterm Infants
  • Lower Respiratory Infection
04

Who can participate

Ages eligible
0 Years to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For the preterm cohort (excluding subjects with CLD or hemodynamically significant CHD): preterm infants in their first year of life and born ≤ 35 weeks 0 days GA eligible to receive palivizumab in accordance with national or local guidelines, including those with:

    1. Uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus, or
    2. Aortic stenosis, pulmonic stenosis, or coarctation of the aorta alone
  2. For the CLD/CHD cohort:

    1. Subjects with CLD - infants in their first year of life and a diagnosis of CLD of prematurity requiring medical intervention/management (ie, supplemental oxygen, bronchodilators, or diuretics) within the 6 months prior to randomization
    2. Subjects with CHD - infants in their first year of life and documented, hemodynamically significant CHD (must be unoperated or partially corrected CHD) Note: Infants with hemodynamically significant acyanotic cardiac lesions must have pulmonary hypertension (≥ 40 mmHg measured pressure in the pulmonary artery) or the need for daily medication to manage CHD
  3. Infants who are entering their first RSV season at the time of screening
  4. Written and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the USA, EU Data Privacy Directive in the EU) obtained from the subject's parent(s)/legal representative(s) prior to performing any protocol-related procedures, including screening evaluations
  5. Subject's parent(s)/legal representative(s) able to understand and comply with the requirements of the protocol including follow-up and illness visits as judged by the investigator
  6. Subject is available to complete the follow-up period, which will be 1 year after Season 1/ Dose 1 for subjects without CLD/CHD, or 1 year after Season 2/Dose 1 (or last replacement dose as applicable for CHD) for subjects with CLD/CHD

Exclusion criteria

Exclusion criteria

  1. Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or acute illness within 7 days prior to randomization
  2. Any history of LRTI or active LRTI prior to, or at the time of, randomization
  3. Known history of RSV infection or active RSV infection prior to, or at the time of, randomization
  4. Hospitalization at the time of randomization, unless discharge is expected within the 7 days after randomization
  5. Requirement for mechanical ventilation, extracorporeal membrane oxygenation, CPAP, or other mechanical respiratory or cardiac support at the time of randomization
  6. Anticipated cardiac surgery within 2 weeks after randomization
  7. Anticipated survival of \< 6 months after randomization
  8. Receipt of any drug
  9. Known renal impairment
  10. Known hepatic dysfunction including known or suspected active or chronic hepatitis infection
  11. congenital anomaly of the respiratory tract
  12. Chronic seizure, or evolving or unstable neurologic disorder
  13. Prior history of a suspected or actual acute life-threatening event
  14. Known immunodeficiency, including (HIV)
  15. Mother with HIV infection (unless the child has been proven to be not infected)
  16. Any known allergy, including to immunoglobulin products, or history of allergic reaction
  17. Receipt of palivizumab or other RSV mAb or any RSV vaccine, including maternal RSV vaccination
  18. Receipt of any monoclonal or polyclonal antibody (for example, immune globulin, intravenous immunoglobulin) or anticipated use during the study
  19. Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of subject safety or study results
  20. Concurrent enrollment in another interventional study
  21. Children of employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
925 participants (actual)

Study arms

  • Experimental
    MEDI8897

    anti-RSV monoclonal antibody with an extended half-life

    Drug: MEDI8897

  • Active comparator
    Palivizumab

    anti-RSV monoclonal antibody

    Drug: Palivizumab

Interventions

  • Anti-RSV monoclonal antibody with an extended half-life

  • Approved anti-RSV monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD)

    Safety and tolerability of MEDI8897 will be assessed by the occurrence of all treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs) , adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs)

    Time frame: 360 days post first dose

Secondary outcomes

  1. Serum Concentrations of MEDI8897 and Palivizumab

    Summary of individual MEDI8897 and palivizumab serum concentration data by treatment group along with descriptive statistics.

    Time frame: Day 15, Day 31, Day 151 post first dose in Season 1 and Season 2

  2. Incidence of Anti-drug Antibody (ADA) to MEDI8897 and Palivizumab in Serum

    Incidence of ADA to MEDI8897 and palivizumab as assessed by the percentage of participants with any post-baseline ADA positive by treatment group.

    Time frame: 360 days post first dose

  3. Incidence of Medically Attended Lower Respiratory Track Infection (LRTI) and Hospitalization Due to Reverse Transcriptase Chain Reaction (RT-PCR) Confirmed Respiratory Syncytial Virus (RSV) Through 150 Days Post First Dose

    Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2. Incidence of LRTI hospitalizations due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2.

    Time frame: 150 days post first dose

07

Results

Posted Sep 21, 2023

Participant flow

In the overall population, 925 infants (615 in preterm cohort, 310 in CLD/CHD cohort) were enrolled from 25 countries and randomized (2:1) to MEDI8897 (n = 616) or palivizumab (n = 309). Of the 310 subjects in the Season 1 CLD/CHD cohort, 262 continued into the Season 2 phase of the study.

Season 1
Participant flow — Season 1
MilestoneMEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/Palivizumab
Started616309000
Completed543263000
Not completed7346000
Withdrew: Other67000
Withdrew: Withdrawal by parent/guardian4328000
Withdrew: Due to covid-19 pandemic23000
Withdrew: Lost to follow-up177000
Withdrew: Death51000
Season 2
Participant flow — Season 2
MilestoneMEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/Palivizumab
Started001804042
Completed001743940
Not completed00612
Withdrew: Other00200
Withdrew: Withdrawal by parent/guardian00311
Withdrew: Lost to follow-up00101

Outcome measures

PrimarySafety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD)

Safety and tolerability of MEDI8897 will be assessed by the occurrence of all treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs) , adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs)

Time frame:
360 days post first dose
Reported as:
Count of participants · Participants
Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD)
ParticipantsMEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/Palivizumab
TEAE4442151303129
TESAE80382342
AESI30100
NOCD30100
SecondarySerum Concentrations of MEDI8897 and Palivizumab

Summary of individual MEDI8897 and palivizumab serum concentration data by treatment group along with descriptive statistics.

Time frame:
Day 15, Day 31, Day 151 post first dose in Season 1 and Season 2
Reported as:
Geometric mean · ug/mL
Serum Concentrations of MEDI8897 and Palivizumab
ug/mLMEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/Palivizumab
Serum concentrations of MEDI8897 and Palivizumab at Day 15104.75 ± 61.866.43 ± 55.7149.38 ± 169.297.70 ± 302.059.62 ± 102.4
Serum concentrations of MEDI8897 and Palivizumab at Day 3185.35 ± 74.248.10 ± 50.089.71 ± 369.5124.89 ± 256.157.77 ± 56.3
Serum concentrations of MEDI8897 and Palivizumab at Day 15125.38 ± 58.8101.56 ± 65.639.86 ± 145.937.95 ± 118.667.66 ± 111.4
SecondaryIncidence of Anti-drug Antibody (ADA) to MEDI8897 and Palivizumab in Serum

Incidence of ADA to MEDI8897 and palivizumab as assessed by the percentage of participants with any post-baseline ADA positive by treatment group.

Time frame:
360 days post first dose
Reported as:
Number · Percentage of participants
Incidence of Anti-drug Antibody (ADA) to MEDI8897 and Palivizumab in Serum
Percentage of participantsMEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/Palivizumab
Incidence of Anti-drug Antibody (ADA) to MEDI8897 and Palivizumab in Serum5.86.911.72.514.3
SecondaryIncidence of Medically Attended Lower Respiratory Track Infection (LRTI) and Hospitalization Due to Reverse Transcriptase Chain Reaction (RT-PCR) Confirmed Respiratory Syncytial Virus (RSV) Through 150 Days Post First Dose

Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2. Incidence of LRTI hospitalizations due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2.

Time frame:
150 days post first dose
Reported as:
Number · Percentage of participants
Incidence of Medically Attended Lower Respiratory Track Infection (LRTI) and Hospitalization Due to Reverse Transcriptase Chain Reaction (RT-PCR) Confirmed Respiratory Syncytial Virus (RSV) Through 150 Days Post First Dose
Percentage of participantsMEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/Palivizumab
Incidence of medically attended RSV LRTI through 150 days post first dose, %0.61.0000
Incidence of medically attended RSV LRTI with hospitalization through 150 days post first dose, %0.30.6000

Adverse events

Collected over Through 360 days post first dose of Season 1 for MEDI8897 and Palivizumab groups, through 360 days post first dose of Season 2 for MEDI8897/MEDI8897, MEDI8897/Palivizumab, and Palivizumab/Palivizumab groups.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MEDI88975/614 (0.8%)80/614 (13%)435/614 (70.8%)
Palivizumab1/304 (0.3%)38/304 (12.5%)211/304 (69.4%)
MEDI8897/MEDI88970/180 (0%)23/180 (12.8%)129/180 (71.7%)
Palivizumab/MEDI88970/40 (0%)4/40 (10%)31/40 (77.5%)
Palivizumab/Palivizumab0/42 (0%)2/42 (4.8%)29/42 (69%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventMEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/Palivizumab
PneumoniaInfections and infestations5/6141/3042/1802/400/42
Bone abscessInfections and infestations0/6140/3040/1801/400/42
Ear infectionInfections and infestations0/6140/3040/1801/400/42
GastroenteritisInfections and infestations6/6141/3043/1801/401/42
Gastrointestinal infectionInfections and infestations0/6140/3040/1801/400/42
Lower respiratory tract infectionInfections and infestations1/6142/3042/1801/400/42
MastoiditisInfections and infestations0/6140/3040/1801/400/42
Otitis mediaInfections and infestations0/6140/3040/1801/400/42
Otitis media acuteInfections and infestations0/6140/3040/1801/400/42
NystagmusNervous system disorders0/6140/3040/1801/400/42
Most frequent other events
Showing 10 of 463
Most frequent other events
EventMEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/Palivizumab
Upper respiratory tract infectionInfections and infestations148/61477/30448/1808/409/42
PyrexiaGeneral disorders81/61443/30423/1809/406/42
NasopharyngitisInfections and infestations57/61439/30426/1807/409/42
Viral upper respiratory tract infectionInfections and infestations33/61414/30414/1808/402/42
DiarrhoeaGastrointestinal disorders29/61411/30410/1802/407/42
RhinitisInfections and infestations75/61440/30429/1806/406/42
Otitis media acuteInfections and infestations16/61414/30411/1805/402/42
Covid-19Infections and infestations8/6142/30414/1803/405/42
VomitingGastrointestinal disorders15/61411/3046/1804/403/42
BronchitisInfections and infestations20/61410/3047/1804/401/42

Baseline characteristics

Age, Continuous
Age, Continuous(Months)MEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/PalivizumabTotal
Age at randomization (months)3.947 ± 2.55133.840 ± 2.4608———3.911 ± 2.5206
Age, Continuous
Age, Continuous(Months)MEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/PalivizumabTotal
Age at first dose of Season 2 (Months)——16.772 ± 2.714116.598 ± 2.433516.132 ± 2.104016.643 ± 2.5857
Sex: Female, Male
Sex: Female, Male(Participants)MEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/PalivizumabTotal
Female297133000430
Male319176000495
Sex: Female, Male
Sex: Female, Male(Participants)MEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/PalivizumabTotal
Female00811515111
Male00992527151
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/PalivizumabTotal
American Indian or Alaska Native11500016
Asian361400050
Native Hawaiian or Other Pacific Islander410005
Black or African American592900088
White483249000732
More than one race6400010
Unknown or Not Reported17700024
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/PalivizumabTotal
American Indian or Alaska Native000000
Asian00103215
Native Hawaiian or Other Pacific Islander001001
Black or African American0092112
White001523538225
More than one race003014
Unknown or Not Reported005005
Congenital heart disease
Congenital heart disease(Participants)MEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/PalivizumabTotal
Yes7034000104
No546275000821
Congenital heart disease
Congenital heart disease(Participants)MEDI8897PalivizumabMEDI8897/MEDI8897Palivizumab/MEDI8897Palivizumab/PalivizumabTotal
Yes0056141181
No001242631181

2 further baseline measures are reported on the registry.

08

Study locations

128 sites
  • Research Site
    Anaheim, California 92804, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    National City, California 91950, United States
  • Research Site
    Paramount, California 90723, United States
  • Research Site
    West Covina, California 91790, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Colorado Springs, Colorado 80922, United States
  • Research Site
    Washington, District of Columbia 20016, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    South Bend, Indiana 46617, United States
  • Research Site
    West Des Moines, Iowa 50266, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Jackson, Mississippi 39216, United States
  • Research Site
    Columbia, Missouri 65201, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Columbus, Ohio 43205, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    Corpus Christi, Texas 78411, United States
  • Research Site
    Layton, Utah 84041, United States
  • Research Site
    Saint George, Utah 84790, United States
  • Research Site
    Charlottesville, Virginia 22902, United States
  • Research Site
    Seattle, Washington 98105, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Montana, 3400, Bulgaria
  • Research Site
    Pazardzhik, 4400, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4003, Bulgaria
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Sliven, 8800, Bulgaria
  • Research Site
    Sofia, 1309, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Veliko Tarnovo, 5000, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 1C9, Canada
  • Research Site
    Vancouver, British Columbia V6H 3V4, Canada
  • Research Site
    Praha 4, 14710, Czechia
  • Research Site
    Tallinn, 13419, Estonia
  • Research Site
    Tartu, 51014, Estonia
  • Research Site
    Tampere, 33100, Finland
  • Research Site
    Amiens Cedex 1, 80054, France
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Bron, 69677, France
  • Research Site
    Caen, 1403, France
  • Research Site
    Creteil Cedex, 94010, France
  • Research Site
    Grenoble Cedex 9, 38043, France
  • Research Site
    Marseille, 13015, France
  • Research Site
    Pau Cedex, 64046, France
  • Research Site
    Frankenthal, 67227, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Mannheim, 68161, Germany
  • Research Site
    Baja, 6500, Hungary
  • Research Site
    Budapest, 1096, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Miskolc, 3526, Hungary
  • Research Site
    Pisa, 56126, Italy
  • Research Site
    Verona, 37126, Italy
  • Research Site
    Fukui-shi, 918-8503, Japan
  • Research Site
    Fukuoka-shi, 813-0017, Japan
  • Research Site
    Kitakyusyu-shi, 806-8501, Japan
  • Research Site
    Maebashi-shi, 371-0811, Japan
  • Research Site
    Saitama shi, 336 8522, Japan
  • Research Site
    Setagaya-ku, 157-8535, Japan
  • Research Site
    Ansan-si, 15355, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Jekabpils, LV-5201, Latvia
  • Research Site
    Riga, 1004, Latvia
  • Research Site
    Riga, LV1002, Latvia
  • Research Site
    Kaunas, 48259, Lithuania
  • Research Site
    Kaunas, 50161, Lithuania
  • Research Site
    Cuernavaca, 62290, Mexico
  • Research Site
    Mexico, 06720, Mexico
  • Research Site
    Christchurch, 8011, New Zealand
  • Research Site
    Bydgoszcz, 85 168, Poland
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Krakow, 31-624, Poland
  • Research Site
    Kraków, 30-348, Poland
  • Research Site
    Wrocław, 51-169, Poland
  • Research Site
    Kazan, 420012, Russian Federation
  • Research Site
    Novosibirsk, 630089, Russian Federation
  • Research Site
    Perm, 614066, Russian Federation
  • Research Site
    Saint Petersburg, 191025, Russian Federation
  • Research Site
    Saint Petersburg, 197341, Russian Federation
  • Research Site
    St Petersburg, 193312, Russian Federation
  • Research Site
    Yaroslavl, 150003, Russian Federation
  • Research Site
    Cape Town, 7505, South Africa
  • Research Site
    Cape Town, 7800, South Africa
  • Research Site
    Johannesburg, 2112, South Africa

Showing the first 100 of 128 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Domachowske J, Madhi SA, Simoes EAF, Atanasova V, Cabanas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186. No abstract available. PubMed 35235733 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in May 2021, 21 months.

Results were first posted in Sep 2023, 2 years 4 months after primary completion. A results delay was requested in Feb 2022.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 22, 2019
StartActual
Jul 30, 2019
Primary completionActual
May 3, 2021
CompletionActual
Jan 20, 2023
Results delay requested
Feb 23, 2022
Results first posted
Sep 21, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03959488
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 22, 2019
Start date
Jul 30, 2019
Primary completion
May 3, 2021
Completion
Jan 20, 2023
Results posted
Sep 21, 2023
Last update
Sep 21, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion